FRI0211 A descriptive analysis of real-world treatment patterns of innovator infliximab (REMICADE) and biosimilar infliximab in a treatment naÏve turkish rheumatologic disease population

Y Yazici,L Xie,D Parenti,A Teeple,L Ellis,A Ogbomo,K Goyal,I Simsek

doi:10.1136/annrheumdis-2017-eular.1117

FRI0211 A descriptive analysis of real-world treatment patterns of innovator infliximab (REMICADE) and biosimilar infliximab in a treatment naÏve turkish rheumatologic disease population

Y Yazici, L Xie + Show 6 more

Open Access

https://doi.org/10.1136/annrheumdis-2017-eular.1117

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2017
Citations: 1

#Innovator Infliximab #Janssen Scientific Affairs + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesThis retrospective healthcare claims analysis examined treatment patterns of innovator infliximab (IFX) and biosimilar infliximab (CT-P13) in a Turkish rheumatologic disease population after CT-P13 availability in July, 2014.MethodsAdult patients (pts)...

Full Text